Sort   by:  
 Page size 
ProteomicsFerroptosis-armed dendritic cell vaccines for glioma immunotherapy
The type of cell death has proven to play a crucial role in cancer immunotherapy efficacy. Immunogenic cell death (ICD) enhances tumor adjuvanticity and antigenicity by releasing danger signals and altering the immune peptidome. The immunogenicity of ferroptosis, an iron-dependent form of cell death...
ORGANISM(S): Mus musculus (Mouse) 
2026-03-17 | PXD060116 | Pride
Glioblastoma Immunogenic cell death (icd) Antigenicity Mouse Ferroptosis Gl261 
TranscriptomicsIntegration of miRNA:mRNA co-expression revealed crucial mechanisms modulated in immunogenic cancer cell death
Immunogenic cell death (ICD) in cancer represents a functionally unique therapeutic response that can induce tumor-targeting immune responses. ICD is characterized by the exposure and release of numerous damage-associated molecular patterns (DAMPs), which confer adjuvanticity to dying cancer cells. ...
ORGANISM(S): Homo sapiens 
2022-08-08 | E-MTAB-11799 | biostudies-arrayexpress
GenomicsImmunogenic cell death inducer cEmsy boosted cancer immunotherapy in lung adenocarcinoma
Immunogenic cell death inducer cEmsy boosted cancer immunotherapy in lung adenocarcinoma
PRJNA1106833 | ENA
UnknownTrial watch: Immunogenic cell death induction by anticancer chemotherapeutics.
Not available
S-EPMC5706600 | biostudies-literature
ProteomicsTarget profiling of organoplatinum(II) complex reveals role of protein tyrosine phosphatase 1B in modulating immunogenicity
Immunogenic cell death (ICD) inducers are valuable chemotherapeutic agents that elicit protective immune responses against tumors. However, the specific molecular targets directly associated with ICD remain less explored. Here, a Type II ICD inducer, Pt-ER, was validated as a bona fide ICD inducer w...
ORGANISM(S): Homo sapiens (Human) 
2026-02-02 | PXD065824 | Pride
Immunogenicity modulation Target identification Immunogenic cell death Chemoproteomics Protein tyrosine phosphatase 1b 
GenomicsTargeting the mevalonate pathway potentiates NUAK1 inhibition-induced immunogenic cell death and antitumor immunity
Targeting the mevalonate pathway potentiates NUAK1 inhibition-induced immunogenic cell death and antitumor immunity
PRJNA1102878 | ENA
UnknownPhysical modalities inducing immunogenic tumor cell death for cancer immunotherapy.
Not available
S-EPMC4352954 | biostudies-literature
UnknownTrial watch: chemotherapy-induced immunogenic cell death in oncology.
Not available
S-EPMC10240992 | biostudies-literature
UnknowneIF2α phosphorylation is pathognomonic for immunogenic cell death.
Not available
S-EPMC6113215 | biostudies-literature
UnknownImmunogenic Cell Death and Immunotherapy of Multiple Myeloma.
Not available
S-EPMC6476910 | biostudies-literature
Sort   by:  
 Page size